NASDAQ : BNGO
Bionano Genomics, Inc. — Key statistics
Healthcare · Medical Instruments & Supplies · United States
Last price 1.2 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 14.13M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 13.54M |
| Enterprise Value | 10.33M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 11.78M |
| Shares Outstanding | 11.78M |
| Shares Change (YoY) | +314.06% |
| Shares Change (QoQ) | +5.16% |
| Owned by Insiders (%) | 0.09% |
| Owned by Institutions (%) | 11.52% |
| Float | 9.47M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.45 |
| Forward PS | 0.37 |
| PB Ratio | 0.43 |
| P/TBV Ratio | 0.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.48 |
| Quick Ratio | 1.42 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -114.16 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -83.56% |
| Return on Assets (ROA) | -32.56% |
| Return on Invested Capital (ROIC) | -38.97% |
| Return on Capital Employed (ROCE) | -85.73% |
| Weighted Average Cost of Capital (WACC) | 10.23% |
| Revenue Per Employee | $311,093 |
| Profits Per Employee | -$331,577 |
| Employee Count | 97 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 2.29 |
Taxes
| Measure | Value |
|---|
| Income Tax | 66,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.71 |
| 52-Week Price Change | -36.81% |
| 50-Day Moving Average | 1.37 |
| 200-Day Moving Average | 1.24 |
| Relative Strength Index (RSI) | 34.68 |
| Average Volume (20 Days) | 195,903 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.36M |
| Short Previous Month | 2.04M |
| Short % of Shares Out | 11.55% |
| Short % of Float | 14.36% |
| Short Ratio (days to cover) | 0.58 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 30.18M |
| Gross Profit | 14.34M |
| Operating Income | -32.19M |
| Pretax Income | -32.10M |
| Net Income | -32.16M |
| EBITDA | -22.67M |
| EBIT | -32.19M |
| Loss Per Share | -$3.37 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 9.92M |
| Total Debt | 6.70M |
| Net Cash | 3.22M |
| Net Cash Per Share | $0.27 |
| Equity (Book Value) | 31.61M |
| Book Value Per Share | 2.68 |
| Working Capital | 14.84M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -20.48M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 9.52M |
| Net Borrowing | -12.22M |
| Free Cash Flow | -20.48M |
| FCF Per Share | -$1.74 |
Margins
| Measure | Value |
|---|
| Gross Margin | 47.50% |
| Operating Margin | -106.68% |
| Pretax Margin | -106.37% |
| Profit Margin | -106.58% |
| EBITDA Margin | -75.12% |
| EBIT Margin | -106.68% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -314.06% |
| Shareholder Yield | n/a |
| Earnings Yield | -293.10% |
| FCF Yield | -151.21% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $5.00 |
| Price Target Difference | 334.78% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 24.33% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 27, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:60 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -22.31 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |